1-3 of 3
G Ledderose
Close
Sort by
Journal Articles

Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study.

G. Hess, MD, D. Bunjes, MD, W. Siegert, MD, R. Schwerdtfeger, MD, G. Ledderose, MD, B. Waßmann, MD, G. Kobbe, MD, M. Bornhäuser, MD, A. Hochhaus, MD, A. J. Ullmann, MD, T. Kindler, MD, H. Geschaidmeier, PhD, C. Huber11, MD, T. Fischer12, MD
Journal: Blood
Blood (2004) 104 (11): 1004.
https://doi.org/10.1182/blood.V104.11.1004.1004
Published: 2004
Journal Articles

Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F)

E Holler, HJ Kolb, J Mittermuller, M Kaul, G Ledderose, T Duell, B Seeber, M Schleuning, R Hintermeier-Knabe, B Ertl
Journal: Blood
Blood (1995) 86 (3): 890–899.
https://doi.org/10.1182/blood.V86.3.890.890
Published: 1995
Journal Articles

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

HJ Kolb, J Mittermuller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim, W Wilmanns
Journal: Blood
Blood (1990) 76 (12): 2462–2465.
https://doi.org/10.1182/blood.V76.12.2462.2462
Published: 1990